| Dennard W Ellison, MD | |
|
106 Blanca Ave, San Luis Valley Regional Medical Center, Alamosa, CO 81101-2340 | |
| (719) 589-8025 | |
| (719) 589-8087 |
| Full Name | Dennard W Ellison |
|---|---|
| Gender | Male |
| Speciality | Allergy/immunology |
| Experience | 38 Years |
| Location | 106 Blanca Ave, Alamosa, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285728659 | NPI | - | NPPES |
| COA100184 | Other | CO | MEDICARE PTAN |
| 00182257 | Medicaid | CO | |
| 52787761 | Medicaid | NM |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 20020441 (New Mexico) | Secondary |
| 207Y00000X | Otolaryngology | 48628 (Colorado) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| San Luis Valley Health | Alamosa, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lutheran Hospital Association Of The San Luis Valley | 4789589094 | 110 |
| Parkview Ancillary Services Corporation | 4385722511 | 267 |
News Archive
A new drug to prevent the early stages of Alzheimer's disease could enter clinical trials in a few years' time according to scientists.
Five technology-based high-tech ventures that have achieved success in the health care field with the assistance of NJIT's Enterprise Development Center (EDC) are the recipients of more than a million dollars in funding awarded in 2009 and 2010 under the federal program Qualifying Therapeutic Discovery Project Grants for the State of New Jersey.
Oncolytics Biotech Inc. today announced that it has met the primary overall statistical endpoint in its U.S. Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel in patients with metastatic stage IIIB, or stage IV, or recurrent SCCLC who are chemotherapy naïve for their metastatic or recurrent cancer (REO 021).
Four in 10 seniors told researchers in a recent national survey that they haven't taken all the drugs their doctors prescribed for them in the past year – either because the costs were too high, because they didn't think the drugs were helping them, or because they didn't think they needed them.
› Verified 8 days ago
| Entity Name | Lutheran Hospital Association Of The San Luis Valley |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235181744 PECOS PAC ID: 4789589094 Enrollment ID: O20031201000318 |
News Archive
A new drug to prevent the early stages of Alzheimer's disease could enter clinical trials in a few years' time according to scientists.
Five technology-based high-tech ventures that have achieved success in the health care field with the assistance of NJIT's Enterprise Development Center (EDC) are the recipients of more than a million dollars in funding awarded in 2009 and 2010 under the federal program Qualifying Therapeutic Discovery Project Grants for the State of New Jersey.
Oncolytics Biotech Inc. today announced that it has met the primary overall statistical endpoint in its U.S. Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel in patients with metastatic stage IIIB, or stage IV, or recurrent SCCLC who are chemotherapy naïve for their metastatic or recurrent cancer (REO 021).
Four in 10 seniors told researchers in a recent national survey that they haven't taken all the drugs their doctors prescribed for them in the past year – either because the costs were too high, because they didn't think the drugs were helping them, or because they didn't think they needed them.
› Verified 8 days ago
| Entity Name | Parkview Ancillary Services Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982878765 PECOS PAC ID: 4385722511 Enrollment ID: O20080429000248 |
News Archive
A new drug to prevent the early stages of Alzheimer's disease could enter clinical trials in a few years' time according to scientists.
Five technology-based high-tech ventures that have achieved success in the health care field with the assistance of NJIT's Enterprise Development Center (EDC) are the recipients of more than a million dollars in funding awarded in 2009 and 2010 under the federal program Qualifying Therapeutic Discovery Project Grants for the State of New Jersey.
Oncolytics Biotech Inc. today announced that it has met the primary overall statistical endpoint in its U.S. Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel in patients with metastatic stage IIIB, or stage IV, or recurrent SCCLC who are chemotherapy naïve for their metastatic or recurrent cancer (REO 021).
Four in 10 seniors told researchers in a recent national survey that they haven't taken all the drugs their doctors prescribed for them in the past year – either because the costs were too high, because they didn't think the drugs were helping them, or because they didn't think they needed them.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dennard W Ellison, MD 106 Blanca Ave, San Luis Valley Regional Medical Center, Alamosa, CO 81101-2340 Ph: (719) 589-8025 | Dennard W Ellison, MD 106 Blanca Ave, San Luis Valley Regional Medical Center, Alamosa, CO 81101-2340 Ph: (719) 589-8025 |
News Archive
A new drug to prevent the early stages of Alzheimer's disease could enter clinical trials in a few years' time according to scientists.
Five technology-based high-tech ventures that have achieved success in the health care field with the assistance of NJIT's Enterprise Development Center (EDC) are the recipients of more than a million dollars in funding awarded in 2009 and 2010 under the federal program Qualifying Therapeutic Discovery Project Grants for the State of New Jersey.
Oncolytics Biotech Inc. today announced that it has met the primary overall statistical endpoint in its U.S. Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel in patients with metastatic stage IIIB, or stage IV, or recurrent SCCLC who are chemotherapy naïve for their metastatic or recurrent cancer (REO 021).
Four in 10 seniors told researchers in a recent national survey that they haven't taken all the drugs their doctors prescribed for them in the past year – either because the costs were too high, because they didn't think the drugs were helping them, or because they didn't think they needed them.
› Verified 8 days ago